Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
45.1M
-
Number of holders
-
94
-
Total 13F shares, excl. options
-
23M
-
Shares change
-
+2.84M
-
Total reported value, excl. options
-
$374M
-
Value change
-
+$50.2M
-
Put/Call ratio
-
1.29
-
Number of buys
-
43
-
Number of sells
-
-58
-
Price
-
$16.26
Significant Holders of Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share (YMAB) as of Q1 2024
115 filings reported holding YMAB - Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share as of Q1 2024.
Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share (YMAB) has 94 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 23M shares
of 45.1M outstanding shares and own 50.98% of the company stock.
Largest 10 shareholders include BlackRock Inc. (2.86M shares), Paradigm Biocapital Advisors LP (2.23M shares), Sofinnova Investments, Inc. (2.19M shares), VANGUARD GROUP INC (2.07M shares), Polar Capital Holdings Plc (1.83M shares), Point72 Asset Management, L.P. (1.53M shares), D. E. Shaw & Co., Inc. (1.07M shares), STATE STREET CORP (751K shares), PICTET ASSET MANAGEMENT Holding SA (746K shares), and GEODE CAPITAL MANAGEMENT, LLC (743K shares).
This table shows the top 94 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.